Page last updated: 2024-11-08

17 alpha-hydroxyprogesterone caproate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID169870
CHEMBL ID1200848
CHEBI ID5812
SCHEMBL ID5330
MeSH IDM0074009

Synonyms (168)

Synonym
MLS002207289
MLS001148643 ,
pregn-4-ene-3,20-dione, 17-[(1-oxohexyl)oxy]-
MLS000028438 ,
17alpha-hydroxyprogesterone caproate
kaprogest
pregn-4-ene-3, 17-[(1-oxohexyl)oxy]-
progesterone caproate
17.alpha.-hydroxyprogesterone hexanoate
delalutin
relutin
proge
hyproval
lutate
syngynon
nsc-17592
hydroxyprogesterone hexanoate
17.alpha.-hydroxyprogesterone n-caproate
progesterone, hexanoate
depo-proluton
pregn-4-ene-3, 17-hydroxy-, hexanoate
proluton depot
neolutin forte
hormofort
nsc17592
estralutin
17.alpha.-hydroxyprogesterone caproate
luteocrin
hyroxon
progesterone, 17-hydroxy-, hexanoate
17-alpha-hydroxyprogesterone caproate
idroprogesterone caproato [dcit]
17 alpha-hydroxyprogesterone caproate
17-alpha-hydroxy progesterone n-caproate
luteocrin depot
17alpha-hydroxyprogesterone n-caproate
hyproval-pa
pregn-4-ene-3,20-dione, 17-hydroxy-, hexanoate
duraluton
17-hydroxypregn-4-ene-3,20-dione hexanoate
idrogestene
17alpha-hydroxyprogesterone-17alpha caproate
lutopron
3,20-dioxopregn-4-en-17alpha-yl caproate
pregn-4-ene-3,20-dione, 17-((1-oxohexyl)oxy)-
17-((1-oxohexyl)oxy)pregn-4-ene-3,20-dione
hylutin
17-alpha-hydroxyprogesterone hexanoate
17-alpha-hexanoyloxypregn-4-ene-3,20-dione
einecs 211-138-8
hydroxyprogesteroni caproas [inn-latin]
gesterol la 250
3,20-dioxo-4-pregnen-17alpha-yl hexanoat
teralutil
hexanoic acid, ester with 17-hydroxypregn-4-ene-3,20-dione
17alpha-hydroxyprogesterone caproate [progestins]
caproato de hidroxiprogesterona [inn-spanish]
progesterone retard pharlon
caproate d'hydroxyprogesterone [inn-french]
primolut depot
17alpha-caproyloxypregn-4-ene-3,20-dione
hydroxyprogesterone caproate
630-56-8
C08148
17alpha-hydroxyprogesterone hexanoate, >=98%
delalutin (tn)
D00949
hylutin (tn)
hydroxyprogesterone caproate (jan/usp/inn)
makena (tn)
smr000058336
17-alpha-hydroxy-progesterone caproate
makena
chebi:5812 ,
oxiprogesterone caproate
17-ohpc
CHEMBL1200848
17.alpha.-caproyloxy-p4
procyte depo
[(10r,13s,17r)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] hexanoate
H0994
17alpha-caproyloxyprogesterone
17alpha-hydroxypregn-4-ene-3,20-diene caproate
[(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] hexanoate;17-caproxyprogesterone
A834188
AKOS005267159
[(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] hexanoate
NCGC00021268-03
dtxcid4023915
cas-630-56-8
NCGC00255784-01
tox21_302333
dtxsid6043915 ,
(1s,11s,15s,2r,10r,14r)-14-acetyl-2,15-dimethyl-5-oxotetracyclo[8.7.0.0<2,7>.0 <11,15>]heptadec-6-en-14-yl hexanoate
tox21_113502
HMS2230L08
S4674
276f2o42f5 ,
gestiva
caproato de hidroxiprogesterona
idroprogesterone caproato
caproate d'hydroxyprogesterone
corlutin l.a.
hydroxyprogesterone caproate [usp:inn:jan]
unii-276f2o42f5
hydroxyprogesteroni caproas
17P ,
17.alpha.-hydroxyprogesterone caproate [mi]
hydroxyprogesterone caproate [who-dd]
17.alpha.-hydroxypregn-4-ene-3,20-dione hexanoate
hydroxyprogesterone caproate [jan]
hydroxyprogesterone caproate [usp monograph]
hydroxyprogesterone caproate [usp-rs]
17-alpha hydroxyprogesterone caproate
3,20-dioxopregn-4-en-17.alpha.-yl caproate
hydroxyprogesterone caproate [mart.]
hydroxyprogesterone caproate [orange book]
hydroxyprogesterone caproate [inn]
hydroxyprogesterone caproate [vandf]
17|a-hydroxyprogesterone caproate
SCHEMBL5330
NCGC00021268-04
tox21_113502_1
(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl hexanoate
17alpha-hexanoyloxy-4pregnene-3,20-dione
17-caproxyprogesterone
Q-201222
cid_169870
bdbm70293
deluteval 2x (salt/mix)
17-hydroxypregn-4-ene-3,20-dione caproate
lewntogest
17-.alpha.-hexanoyloxypregn-4-ene-3,20-dione
17.alpha.-hydroxypregn-4-ene-3,20-dione caproate
3,20-dioxopregn-4-en-17.alpha.-yl hexanoate #
hyproval p.a.
HY-B0742
OPERA_ID_1479
DB06789
17alpha-hydroxyprogesterone hexanoate
mfcd00072134
17a-hydroxyprogesterone caproate
(1s,2r,10r,11s,14r,15s)-14-acetyl-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl hexanoate
GS-3233
sr-01000003075
SR-01000003075-3
hydroxyprogesterone caproate, united states pharmacopeia (usp) reference standard
17alpha-hydroxyprogesteron-caproat
BCP16081
Q3792032
17|a-hydroxyprogesterone hexanoate
17a-hydroxyprogesterone hexanoate
17-hydroxyprogesterone-caproate
CCG-268987
H10189
17-hydroxyprogesterone hexanoate;17-hydroxyprogesterone caproate
17 alpha -hydroxyprogesterone caproate
(1r,3as,3br,9ar,9bs,11as)-1-acetyl-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl hexanoate
EN300-7422372
caproato de hidroxiprogesterona (inn-spanish)
17alpha-hydroxypregn-4-ene-3,20-dione hexanoate
hydroxyprogesterone caproate (mart.)
hydroxyprogesteroni caproas (inn-latin)
caproate d'hydroxyprogesterone (inn-french)
hydroxyprogesterone caproate (usp-rs)
17alpha-caproyloxy-p4
hydroxyprogesterone caproate (usp:inn:jan)
hydroxyprogesterone caproate (usp monograph)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No serious adverse effect where recorded during the study period."( Efficacy and safety of 17alpha-hydroxyprogesterone caproate in hormone replacement therapy.
Agostini, R; Casini, ML; Costabile, L; Marzano, F; Paragona, M; Unfer, V, 2005
)
0.33
" The current search of the non-clinical literature was performed to identify whether there were any signals from studies in animals that might suggest concerns for the safe use of progestins generally, and 17-OHP-C specifically, in the prevention of preterm birth in humans."( Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
Brent, RL; Calda, P; Christian, MS, 2007
)
0.34
" The biological plausibility for 17-OHPC to be associated with adverse outcomes can be suggested from pharmacogenomic observations, ex vivo experimentation, and clinical observations."( The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
O'Brien, JM, 2012
)
0.38
" Independent phase III trials and an individual patient metaanalysis suggest that vaginal progesterone is efficacious and safe in women with a singleton and a short cervix."( Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
Lewis, DF; O'Brien, JM, 2016
)
0.43
" Similar findings with low and comparable rates between 17P and placebo were also found for other adverse events."( Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth.
Das, AF; Gudeman, J; Saade, GR; Sibai, B, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation."( Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sharma, S; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Venkataramanan, R, 2011
)
0.37
" Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis."( Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sharma, S; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Venkataramanan, R, 2011
)
0.37
"The apparent half-life of 17-OHPC was 10 days."( Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sharma, S; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Venkataramanan, R, 2011
)
0.37
"This is the first pharmacokinetic analysis of 17-OHPC in pregnant women."( Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sharma, S; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Venkataramanan, R, 2011
)
0.37
" Plasma concentrations of 17-OHPC were measured by LC-MS-MS and pharmacokinetic parameters were calculated by non-compartmental analysis, using WinNonLin (Certara, St."( Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats.
Bastian, JR; Caritis, SN; Shaik, IH; Venkataramanan, R; Zhao, Y, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"In a prospective and randomized study comprising 540 primary endometrial carcinoma patients the influence of adjuvant hormone therapy by Oxyprogesterone caproate (OPC) and by its combination with Tamoxifen on the corrected survival rates after surgical and combined (surgical and irradiation) therapy was investigated."( Favourable influence of adjuvant hormone therapy by oxyprogesterone caproate (OPC) and by its combination with tamoxifen on 5-year survival rate of surgical and combined treatment of primary endometrial carcinoma patients.
Loutfi, G; Vishnevsky, AS, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" We hypothesized that 17-OHPC could reduce mean arterial pressure by decreasing inflammation, whereas improving vasodilation by increasing nitric oxide bioavailability and uterine artery resistance index during late gestation in the reduced uterine perfusion pressure (RUPP) rat model of preeclampsia."( 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.
Amaral, LM; Cornelius, DC; Harmon, A; LaMarca, B; Martin, JN; Moseley, J, 2015
)
0.42
" The bioavailability was nearly 100% after IM administration, but was very low (<3%) after PO administration of a solution dosage form."( Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats.
Bastian, JR; Caritis, SN; Shaik, IH; Venkataramanan, R; Zhao, Y, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"A high-pressure liquid chromatography method for the quantitation of hydroxyprogesterone caproate, medroxyprogesterone acetate, and progesterone in pharmaceutical dosage forms was developed."( Quantitation of hydroxyprogesterone caproate, medroxyprogesterone acetate, and progesterone by reversed-phase high-pressure liquid chromatography.
Das Gupta, V, 1982
)
0.26
"A high-performance liquid chromatographic (HPLC) method for the quantitative determination of meperidine hydrochloride in pharmaceutical dosage forms was developed."( Quantitation of meperidine hydrochloride in pharmaceutical dosage forms by high-performance liquid chromatography.
Das Gupta, V, 1983
)
0.27
" A total dosage was 5,0; 10,0; 20,0 and 30,0 for the course of treatment."( [Clinico-morphological changes during treatment of endometrial cancer with progestins].
Gosh, TE; Nevskaia, EA; Nikitina, NI; Shuvaeva, NI; Vekhova, LI, 1980
)
0.26
" The steroid did not exert a significant influence on any assessed parameter of endochondral bone development or growth, even at a dosage concentration that far exceeded the human therapeutic dose equivalent."( Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse.
Brent, RL; Carbone, JP, 1993
)
0.51
"5 kg/m(2)), and less common in obese women (BMI ≥30 kg/m(2)) suggesting that the current recommended dosing of 17 P is adequate for women with higher BMI."( Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
Boyle, A; Driggers, RW; Feghali, M; Istwan, N; Rhea, D; Timofeev, J, 2013
)
0.39
" Progesterone formulations and dosage regimens varied greatly between studies."( The rebirth of progesterone in the prevention of preterm labor.
Fan-Havard, P; Franco, A; Prescott, GM; Schmouder, VM, 2013
)
0.39
" This observation is consistent with pharmacological studies suggesting that dosing regimens of 17OHP-C may affect efficacy."( Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Co, AL; Hade, EM; Iams, JD; Walker, HC, 2015
)
0.42
" The bioavailability was nearly 100% after IM administration, but was very low (<3%) after PO administration of a solution dosage form."( Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats.
Bastian, JR; Caritis, SN; Shaik, IH; Venkataramanan, R; Zhao, Y, 2016
)
0.43
" These studies have increased the understanding of this drug and how the polymorphs may affect its physical stability in different dosage forms."( Characterization of new crystalline forms of hydroxyprogesterone caproate.
Caplette, J; Frigo, T; Jozwiakowski, M; Mirmehrabi, M; Müller, P; Shea, H, 2017
)
0.46
" Alternative dosing protocols and treatment discontinuation are the only available therapeutic strategies."( Anti-allodynic and anti-inflammatory effects of 17α-hydroxyprogesterone caproate in oxaliplatin-induced peripheral neuropathy.
Coronel, MF; Gonzalez, SL; Miguel, CA; Raggio, MC; Villar, MJ, 2019
)
0.51
" Progesterone supplements are believed to reduce the rate of preterm labor, but formulation, type of administration, and dosage varies in different studies."( Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
Alizadeh, F; Mahmoudinia, M; Mirteimoori, M; Niroumand, S; Pourali, L, 2022
)
0.72
" With the absence of fundamental pharmacologic studies addressing dosing or the relationship between drug concentration and gestational age at delivery, the effectiveness of the medication cannot be evaluated."( Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis, SN; Chauhan, SP; Clark, S; Costantine, MM; Kiley, JW; Metz, TD; Stika, CS; Venkataramanan, R, 2023
)
0.91
" Maternal and neonatal safety outcomes were similar in both dosing groups."( Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis, SN; Chauhan, SP; Clark, S; Costantine, MM; Kiley, JW; Metz, TD; Stika, CS; Venkataramanan, R, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (66)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID485281
glp-1 receptor, partialHomo sapiens (human)Potency12.58930.01846.806014.1254AID624417
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency40.01643.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.13420.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency17.54300.173734.304761.8120AID1346859; AID1346924
Fumarate hydrataseHomo sapiens (human)Potency17.78280.00308.794948.0869AID1347053
SMAD family member 3Homo sapiens (human)Potency17.54300.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency12.47330.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency29.21920.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency11.22020.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency8.12690.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency8.91250.00527.809829.0929AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency3.98110.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency19.52230.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency71.75960.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency16.84140.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.94970.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.23100.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency43.78900.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency10.24170.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.85370.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency35.03030.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency10.75140.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.27790.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency4.89750.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency13.80290.00108.379861.1304AID1645840
polyproteinZika virusPotency17.78280.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency17.78280.00018.4406100.0000AID720579
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency25.86570.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.09660.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency30.87500.023723.228263.5986AID743222; AID743223; AID743241
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency27.28410.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency30.40570.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency9.66620.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency4.608819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency48.64290.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency125.94300.039147.5451146.8240AID1224845
Caspase-7Cricetulus griseus (Chinese hamster)Potency76.41130.006723.496068.5896AID1346980
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency20.59620.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency17.78283.548119.542744.6684AID743266
caspase-3Cricetulus griseus (Chinese hamster)Potency76.41130.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency13.68700.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency50.69490.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency10.00000.000618.41981,122.0200AID1688
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency15.23280.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency18.20030.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency19.95260.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency19.95260.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency37.40780.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency4.89750.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency4.89750.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency53.13030.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency37.40780.001551.739315,848.9004AID1259244
Alpha-synucleinHomo sapiens (human)Potency35.48130.56239.398525.1189AID652106
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.70790.009610.525035.4813AID1479145
Guanine nucleotide-binding protein GHomo sapiens (human)Potency25.11891.995325.532750.1187AID624288
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency4.89750.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency4.89750.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)192.44000.018023.2882287.6000AID434968; AID435010
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
replicative DNA helicaseMycobacterium tuberculosis H37RvAC506.97650.057030.7482325.3000AID449749; AID449750
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (245)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (73)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (50)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1209740Drug uptake in sandwich-cultured human fetal hepatocytes at 1 uM after 20 mins in presence of cold media at 4 degC by liquid scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1209741Drug uptake in sandwich-cultured human fetal hepatocytes at 1 uM after 20 mins in presence of warm media at 37 degC by liquid scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209762Drug excretion in sandwich-cultured human adult hepatocytes assessed as mean biliary index2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209757Inhibition of ABCB11-mediated taurocholate total uptake in sandwich-cultured human fetal hepatocytes at >0.5 uM2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209765Drug accumulation in sandwich-cultured human adult hepatocytes assessed per mg protein under Ca2+/Mg2+ free conditions2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209742Drug uptake in sandwich-cultured human adult hepatocytes at 1 uM after 20 mins in presence of cold media at 4 degC by liquid scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1209759Inhibition of ABCB11-mediated taurocholate total uptake in sandwich-cultured human adult hepatocytes at >50 uM2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1150121Relative binding affinity to human progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1209743Drug uptake in sandwich-cultured human adult hepatocytes at 1 uM after 20 mins in presence of warm media at 37 degC by liquid scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209769Cmax in adult human cold blood2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1209767Drug accumulation in sandwich-cultured human fetal hepatocytes assessed per mg protein under Ca2+/Mg2+ free conditions2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209764Drug accumulation in sandwich-cultured human adult hepatocytes assessed per mg protein under Ca2+/Mg2+ conditions2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209763Drug excretion in sandwich-cultured human fetal hepatocytes assessed as mean biliary index2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209766Drug accumulation in sandwich-cultured human fetal hepatocytes assessed per mg protein under Ca2+/Mg2+ conditions2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209768Cmax in adult human plasma2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209758Inhibition of ABCB11-mediated taurocholate efflux in sandwich-cultured human adult hepatocytes at 5 to 100 uM2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1209756Inhibition of ABCB11-mediated taurocholate efflux in sandwich-cultured human fetal hepatocytes at 0.5 to 10 uM2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (497)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990120 (24.14)18.7374
1990's34 (6.84)18.2507
2000's76 (15.29)29.6817
2010's197 (39.64)24.3611
2020's70 (14.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.21 (24.57)
Research Supply Index6.41 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials88 (17.02%)5.53%
Reviews59 (11.41%)6.00%
Case Studies15 (2.90%)4.05%
Observational3 (0.58%)0.25%
Other352 (68.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Comparison of Intramuscular and Subcutaneous Administration of 17-hydroxyprogesterone Caproate (17-OHPC) in Pregnancy [NCT04183452]24 participants (Actual)Observational2020-06-16Terminated(stopped due to Sponsor stopped study as the study drugs were withdrawn from the market)
Use of 17α Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor During Current Pregnancy. Double Blind, Randomized, Controlled Trial. [NCT01317225]Phase 380 participants (Anticipated)Interventional2011-06-30Recruiting
17-Alpha-Hydroxyprogesterone Caproate for Reduction of Neonatal Morbidity Due to Preterm Birth in Twin and Triplet Pregnancies - A Concurrent Randomized Double-blinded Clinical Trial [NCT00163020]Phase 2/Phase 3321 participants (Actual)Interventional2004-11-30Completed
Progestagens for the Tertiary Prophylaxis of Preterm Delivery in Women With Short Cervix. A Randomized Multicentre Trial [NCT01178788]Phase 3254 participants (Actual)Interventional2010-02-28Completed
Relationship Between Plasma Concentration of (Hydroxyprogesterone Caproate) 17-OHPC and Preterm Birth [NCT03292731]Phase 1/Phase 2159 participants (Actual)Interventional2018-02-12Terminated(stopped due to grant funding cycle ended)
Impact of a Higher Dose on the Pharmacokinetics of 17-alpha Hydroxyprogesterone Caproate in Obese Women [NCT03433040]Phase 344 participants (Actual)Interventional2017-08-23Completed
The Use Of Intramuscular Hydroxyprogesterone Caproate For Management Of Placenta Previa Before 34 Weeks Of Gestation [NCT03130504]Phase 2130 participants (Actual)Interventional2016-04-01Completed
A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-inj [NCT02940522]Phase 1122 participants (Actual)Interventional2016-09-30Completed
Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy [NCT03297216]Phase 3800 participants (Actual)Interventional2018-02-07Completed
Comparing Intramuscular Versus Vaginal Progesterone for Prevention of Preterm Birth. [NCT00579553]174 participants (Actual)Interventional2006-10-31Completed
Luteal Phase Support Using Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone Supplementation in High Responders Following GnRHa Triggering - A Prospective Randomized Controlled Trial [NCT04797338]Phase 4100 participants (Anticipated)Interventional2017-12-29Recruiting
[NCT00809939]Phase 3800 participants (Anticipated)Interventional2010-12-31Active, not recruiting
Histologic Evaluation of the Cervix at Risk for Preterm Birth Trial:Medical Versus Surgical Therapy [NCT00694967]92 participants (Actual)Interventional2003-11-30Terminated(stopped due to Interim analysis showed no difference in outcome between treatment groups.)
A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via [NCT02937766]Phase 360 participants (Actual)Interventional2016-10-07Terminated(stopped due to The Sponsor elected to discontinue the study prematurely due to business reasons)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial [NCT01119963]Phase 2/Phase 3152 participants (Actual)Interventional2011-10-31Completed
Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study [NCT04077853]Phase 480 participants (Actual)Interventional2019-12-15Completed
The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial [NCT00123669]Phase 2/Phase 31,000 participants (Actual)Interventional1997-10-31Completed
A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS) [NCT00099164]Phase 3795 participants (Actual)Interventional2004-04-30Completed
A Randomized Trial of Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in Pregnancies at High Risk [NCT00135902]Phase 3800 participants (Actual)Interventional2005-02-28Completed
Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate [NCT00141908]Phase 2290 participants (Anticipated)Interventional2006-10-31Completed
A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Nulliparous Women With a Short Cervix [NCT00439374]Phase 3657 participants (Actual)Interventional2007-04-30Terminated(stopped due to Halted by NICHD after recommendation by DSMC to stop for futility)
Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes [NCT04807543]Phase 2100 participants (Actual)Interventional2018-01-10Completed
[NCT00120640]0 participants (Actual)Interventional2005-07-31Withdrawn(stopped due to funding)
A Study of the Pharmacology of 17-Hydroxyprogesterone Caproate in Pregnancy [NCT00409825]Phase 261 participants (Actual)Interventional2006-03-31Completed
The Impact of Progesterone Treatment on Obstetrical Outcome Among Women With First Trimester Vaginal Bleeding [NCT01501890]0 participants (Actual)Interventional2012-01-31Withdrawn(stopped due to never started)
Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial. [NCT01050647]Phase 1/Phase 221 participants (Actual)Interventional2010-02-28Completed
A Phase 3B, Multi-Center, Randomized, Double-Blind Study of Hydroxyprogesterone Caproate (HPC) Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery [NCT01004029]Phase 31,740 participants (Actual)Interventional2009-10-31Completed
A Multi-Center, Non-Randomized Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood of Women With a Singleton Pregnancy and a Previous Singleton Spontaneous Preterm Delivery [NCT01899846]Phase 130 participants (Actual)Interventional2013-07-31Completed
Evaluation of the Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery [NCT00331695]Phase 4560 participants (Actual)Interventional2006-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00163020 (17) [back to overview]Individual Components of Neonatal Morbidity (RDS, IVH-III/IV, Bronchopulmonary Dysplasia(BPD), PVL, Sepsis, NEC, ROP-Stage 3/4, Perinatal Death)
NCT00163020 (17) [back to overview]Newborn Asphyxia With Ischemic Injury of Brain, Heart, Kidneys, or Liver
NCT00163020 (17) [back to overview]Newborn Birthweight
NCT00163020 (17) [back to overview]Newborn Gestational Age (GA) at Delivery
NCT00163020 (17) [back to overview]Newborn Intraventricular Hemorrhage Grade 3 or 4
NCT00163020 (17) [back to overview]Newborn Necrotizing Enterocolitis (NEC)Requiring Surgery
NCT00163020 (17) [back to overview]Newborn Periventricular Leukomalacia (PVL)
NCT00163020 (17) [back to overview]Newborn Pneumonia
NCT00163020 (17) [back to overview]Newborn Respiratory Distress Syndrome (RDS)
NCT00163020 (17) [back to overview]Newborn Retinopathy of Prematurity (ROP)
NCT00163020 (17) [back to overview]Newborn Sepsis
NCT00163020 (17) [back to overview]Participant Drop-out Rates
NCT00163020 (17) [back to overview]Participant Side Effects Requiring Cessation of Therapy
NCT00163020 (17) [back to overview]Perinatal Death
NCT00163020 (17) [back to overview]Use of Oxygen Therapy at 28 Days of Newborn Life
NCT00163020 (17) [back to overview]Triplets: Delivery Prior to 28 Wks, 32 Wks, 35 Wks
NCT00163020 (17) [back to overview]Twins: Delivery Prior to 28 Weeks (Wks), 32 Wks, 34wks, and 37 Wks
NCT00409825 (1) [back to overview]Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy.
NCT00439374 (27) [back to overview]Mean Birth Weight
NCT00439374 (27) [back to overview]Number of Participants Who Reported Side Effects
NCT00439374 (27) [back to overview]Number of Participants Meeting the Composite Adverse Perinatal Outcome and Components
NCT00439374 (27) [back to overview]Number of Participants Delivering Before 37 Weeks Gestation
NCT00439374 (27) [back to overview]Number of Neonates Who Measured Small for Gestational Age
NCT00439374 (27) [back to overview]Birth Weight by Count of Participants
NCT00439374 (27) [back to overview]Number of Participants With Preterm Premature Rupture of Membranes
NCT00439374 (27) [back to overview]Number of Participants With Gestational Diabetes Mellitus
NCT00439374 (27) [back to overview]Number of Participants With Apgar Score of Less Than 7 at 5 Minutes
NCT00439374 (27) [back to overview]Number of Participants Who Visited the Hospital Due to Preterm Labor
NCT00439374 (27) [back to overview]Number of Participants Who Underwent Tocolytic Therapy
NCT00439374 (27) [back to overview]Number of Participants Who Underwent Corticosteroid Therapy
NCT00439374 (27) [back to overview]Number of Participants Who Had Cesarean Delivery
NCT00439374 (27) [back to overview]Number of Participants Who Had a Cerclage Placement
NCT00439374 (27) [back to overview]Number of Participants Who Experienced Placental Abruption
NCT00439374 (27) [back to overview]Number of Participants Who Experienced Chorioamnionitis
NCT00439374 (27) [back to overview]Number of Participants Who Delivered Before 35 Weeks Gestation
NCT00439374 (27) [back to overview]Number of Participants Who Delivered Before 32 Weeks Gestation
NCT00439374 (27) [back to overview]Number of Neonates With a Major Congenital Anomaly
NCT00439374 (27) [back to overview]Number of Participants Who Delivered Before 28 Weeks Gestation
NCT00439374 (27) [back to overview]Number of Participants Experiencing Gestational Hypertension or Preeclampsia
NCT00439374 (27) [back to overview]Number of Participants Experiencing Cholestasis
NCT00439374 (27) [back to overview]Number of Neonates With Patent Ductus Arteriosus
NCT00439374 (27) [back to overview]Number of Neonates Experiencing Seizures
NCT00439374 (27) [back to overview]Number of Neonates Admitted to NICU
NCT00439374 (27) [back to overview]Median Length of NICU Stay
NCT00439374 (27) [back to overview]Mean Gestational Age at Delivery
NCT00579553 (4) [back to overview]Preterm Birth
NCT00579553 (4) [back to overview]Gestational Age at Delivery
NCT00579553 (4) [back to overview]Mean Neonatal Birth Weight
NCT00579553 (4) [back to overview]Preterm Birth
NCT01004029 (7) [back to overview]Preterm Birth Prior to 37 Weeks Gestation
NCT01004029 (7) [back to overview]Preterm Birth Prior to 32 Weeks Gestation
NCT01004029 (7) [back to overview]Preterm Birth <35 Weeks Gestation
NCT01004029 (7) [back to overview]Neonatal Deaths With ≥24 Weeks Gestational Age
NCT01004029 (7) [back to overview]Fetal/Early Infant Death
NCT01004029 (7) [back to overview]Neonatal Composite Index (NCI)
NCT01004029 (7) [back to overview]Stillbirths
NCT01050647 (6) [back to overview]Number of Participants With Achievement of 34 Weeks Gestation
NCT01050647 (6) [back to overview]Number of Participants With Neonatal Respiratory Distress Syndrome
NCT01050647 (6) [back to overview]Number of Participants With Neonatal Necrotizing Enterocolitis
NCT01050647 (6) [back to overview]Number of Participants With Neonatal Grade III - IV Intraventricular Hemorrhage
NCT01050647 (6) [back to overview]Neonatal Length of NICU and Total Hospital Stay Assessed as Number of Days
NCT01050647 (6) [back to overview]Length of Latency Assessed as Number of Days
NCT01119963 (2) [back to overview]Gestational Age at Delivery
NCT01119963 (2) [back to overview]Duration of Latency Period
NCT02937766 (3) [back to overview]Clinician Assessment of Ease of Drug Preparation
NCT02937766 (3) [back to overview]Clinician Assessment of Ease of Injection Technique
NCT02937766 (3) [back to overview]Comparison of Average Pain Intensity
NCT02940522 (6) [back to overview]Comparison of AUC (0-168)
NCT02940522 (6) [back to overview]Comparison of t1/2
NCT02940522 (6) [back to overview]Comparison of Elimination Rate Constant
NCT02940522 (6) [back to overview]Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf]
NCT02940522 (6) [back to overview]Comparison of Tmax
NCT02940522 (6) [back to overview]Comparison of the Maximum Plasma Concentration (Cmax)
NCT03292731 (7) [back to overview]Survival A
NCT03292731 (7) [back to overview]Relationship Between 17-OHPC Concentration and Spontaneous Preterm Birth - A Concentration-Response Analysis
NCT03292731 (7) [back to overview]Preterm Birth by Dosing Group
NCT03292731 (7) [back to overview]NICU Admission
NCT03292731 (7) [back to overview]Composite Neonatal Outcome
NCT03292731 (7) [back to overview]Survival B
NCT03292731 (7) [back to overview]Comparison of Plasma Concentration of 17-OHPC According to Dose
NCT03297216 (14) [back to overview]Number of Infants With 1-minute Apgar Score <7
NCT03297216 (14) [back to overview]Number of Infants With Birth Weight <10th Percentile for Gestational Age
NCT03297216 (14) [back to overview]Number of Neonatal Deaths
NCT03297216 (14) [back to overview]Number of Participants Experiencing Preterm Birth <28 Weeks
NCT03297216 (14) [back to overview]Number of Participants Experiencing Preterm Birth <34 Weeks
NCT03297216 (14) [back to overview]Number of Participants Experiencing Preterm Birth <37 Weeks
NCT03297216 (14) [back to overview]Number of Infants With Birth Weight <3rd Percentile for Gestational Age
NCT03297216 (14) [back to overview]Number of Participants Experiencing Preterm Births or Stillbirths
NCT03297216 (14) [back to overview]Number of Infants Who Experienced Maternal-to-Child HIV Transmission
NCT03297216 (14) [back to overview]Number of Participants Experiencing Spontaneous Delivery <28 Weeks
NCT03297216 (14) [back to overview]Number of Participants Experiencing Spontaneous Delivery <34 Weeks
NCT03297216 (14) [back to overview]Number of Participants Experiencing Spontaneous Delivery <37 Weeks
NCT03297216 (14) [back to overview]Number of Participants Experiencing Stillbirth
NCT03297216 (14) [back to overview]Number of Infants With 5-minute Apgar Score <7
NCT03433040 (2) [back to overview]Change in Mean Trough Levels of 17-OHPC in the Three Groups at 20-22 Weeks, 27-29 Weeks and 34-36 Weeks.
NCT03433040 (2) [back to overview]Gestational Age at Delivery

Individual Components of Neonatal Morbidity (RDS, IVH-III/IV, Bronchopulmonary Dysplasia(BPD), PVL, Sepsis, NEC, ROP-Stage 3/4, Perinatal Death)

Composite Neonatal Morbidity within the twin group is described as the presence of any one or more of the following neonatal morbidities (RDS, IVH-III/IV, BPD, PVL, sepsis, NEC, ROP-Stage 3/4, Perinatal Death). (NCT00163020)
Timeframe: measured as any event noted in the first 28 day following birth.

InterventionTwins - Components of Neonatal Morbidity (Number)
Twins Group = Test Arm - 17OHP46
Twins Group - Placebo Arm19

[back to top]

Newborn Asphyxia With Ischemic Injury of Brain, Heart, Kidneys, or Liver

Newborn Asphyxia or Hypoxic-ischemic encephalopathy (HEI) within the twin group is characterized by clinical and laboratory evidence of acute or subacute brain injury due to asphyxia (ie, hypoxia, acidosis). (NCT00163020)
Timeframe: measured during the first 28 days after delivery

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP0
Twins Group - Placebo Arm0

[back to top]

Newborn Birthweight

Newborn Birthweight within the twins group was measure following delivery and noted in grams. (NCT00163020)
Timeframe: measure following delivery

Interventiongrams (Mean)
Twins Group = Test Arm - 17OHP2321
Twins Group - Placebo Arm2469

[back to top]

Newborn Gestational Age (GA) at Delivery

Newborn Gestational age at delivery within the twin group is described as the gestational age of the baby on the day of birth. (NCT00163020)
Timeframe: determined at the time of birth

Interventionweeks of age for twin pregnancy (Mean)
Twins Group = Test Arm - 17OHP35.3
Twins Group - Placebo Arm35.9

[back to top]

Newborn Intraventricular Hemorrhage Grade 3 or 4

"Newborn Intraventricular hemorrhage (IVH) Stage III in the twin group is described as - IVH with ventricular dilatation.~Neonatal Intraventricular hemorrhage (IVH)Stage IV in the twin group is described as - IVH with parenchymal extension." (NCT00163020)
Timeframe: measured during the first 28 days after birth

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP3
Twins Group - Placebo Arm0

[back to top]

Newborn Necrotizing Enterocolitis (NEC)Requiring Surgery

Newborn NEC in the twin group is described as the presence of any of the following: (1)unequivocal intramural air in abdominal radiograph; (2) perforation abdominal radiograph; (3) clinical evidence of perforation (erythema and induration of the abdominal wall or intrabdominal abscess formation); (4) characteristic findings observed at surgery or autopsy; (5) Stricture formation after an episode of suspected necrotizing enterocolitis. (NCT00163020)
Timeframe: measured in the first 28 days after birth

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP0
Twins Group - Placebo Arm0

[back to top]

Newborn Periventricular Leukomalacia (PVL)

Newborn Periventricular leukomalacia (PVL) in the twin group is described as the presence of more than 1 obvious hypo echoic cyst in the periventricular white matter. (NCT00163020)
Timeframe: measured in the first 28 days after birth.

Interventionparticipants (Number)
Twins Group = Test Arm - 17OHP1
Twins Group - Placebo Arm1

[back to top]

Newborn Pneumonia

Newborn Pneumonia in the twin group is described as compatible symptoms with diagnostic radiograph findings and positive results on blood cultures, persistent leukopenia (NCT00163020)
Timeframe: measure during the first 28 days after birth.

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP1
Twins Group - Placebo Arm0

[back to top]

Newborn Respiratory Distress Syndrome (RDS)

"Newborn RDS in the twin arm is defined as compatible symptoms with radiographically confirmed hyaline membrane disease or with respiratory insufficiency of prematurity requiring ventilator support.~Data expressed as mean n(%),Odds ratio, CI, and P-value were determined using repeated measures model wherein each twin/triplet within a given pregnancy is considered a repeated measure. Exceptions are comparison with 0 outcomes in one or both groups, so Fisher's Exact Test was used.~Morbidity measures were based on live births with data available for the outcomes." (NCT00163020)
Timeframe: Measured from delivery until 30 days after baby was discharged from the hospital

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP44
Twins Group - Placebo Arm18

[back to top]

Newborn Retinopathy of Prematurity (ROP)

Newborn ROP within the twin group is described as retinopathy confirmed on fundoscopic examination, felt to be due to prematurity and subsequent oxygen therapy. (NCT00163020)
Timeframe: measured during the first 28 day after birth

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP2
Twins Group - Placebo Arm0

[back to top]

Newborn Sepsis

Newborn Sepsis in the twin group was defined as the presence of positive blood culture obtained in the first week of life in association with clinical findings suggesting illness for which the neonate received antibiotics. (NCT00163020)
Timeframe: measured during the first week following birth

Interventionparticipants (Number)
Twins Group = Test Arm - 17OHP3
Twins Group - Placebo Arm1

[back to top]

Participant Drop-out Rates

Drop-out rates in the twin group are described as any randomized participant who is withdrawn from the trial between randomization (as early at 16 weeks of pregnancy) and completion of the final dose of study medication (as late as 34 weeks of pregnancy). (NCT00163020)
Timeframe: any time from randomization to completion of final dose of study medication

Interventionparticipants (Number)
Twins Group = Test Arm - 17OHP8
Twins Group - Placebo Arm5

[back to top]

Participant Side Effects Requiring Cessation of Therapy

Describe as the cessation of study related therapy for the participant within the twin group at anytime from initial study related injection until the final injection at 34 weeks of pregnancy. (NCT00163020)
Timeframe: anytime from initial injection to final injection at 34 weeks.

Interventionparticipants (Number)
Twins Group = Test Arm - 17OHP6
Twins Group - Placebo Arm0

[back to top]

Perinatal Death

Perinatal death within the twin group is described as a stillbirth, neonatal death, or miscarriage after randomization. (NCT00163020)
Timeframe: measured from randomization to 28 days after birth.

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP0
Twins Group - Placebo Arm3

[back to top]

Use of Oxygen Therapy at 28 Days of Newborn Life

Supplemental oxygen use by the baby measured at the point that the baby reaches 28 days old (after birth)within the twin group. (NCT00163020)
Timeframe: Measured at 28 days after birth.

InterventionTwins (Number)
Twins Group = Test Arm - 17OHP9
Twins Group - Placebo Arm0

[back to top]

Triplets: Delivery Prior to 28 Wks, 32 Wks, 35 Wks

Gestational age was noted at time of delivery and stratified into three categories (Triplets: Delivery prior to 28 wks, 32 wks, 35 wks) (NCT00163020)
Timeframe: noted at delivery

,
InterventionTriplet Pregnancies (Number)
Delivery before 28 weeks of gestationDelivery before 32 weeks of gestationDelivery before 35 weeks of gestation
Triplet Group - Placebo Arm21313
Triplet Group = Test Arm - 17OHP91943

[back to top]

Twins: Delivery Prior to 28 Weeks (Wks), 32 Wks, 34wks, and 37 Wks

Gestational age was noted at time of delivery and stratified into three categories (Twins: Delivery prior to 28 weeks (wks), 32 wks, 34 wks, and 37 wks) (NCT00163020)
Timeframe: Gestational age noted at time of birth

,
InterventionTwin Pregnancies (Number)
Delivery before 28 weeks of gestationDelivery before 32 weeks of gestationDelivery before 34 weeks of gestationDelivery before 37 weeks of gestation
Twins Group - Placebo Arm141146
Twins Group = Test Arm - 17OHP31531113

[back to top]

Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy.

"Change in the area under the concentration vs. time curve in the second and third trimesters of pregnancy.~We compared AUC at each PK study visit. Measurements were obtained at 0, 1, 2, 3, 4, 5, 6, 7 days." (NCT00409825)
Timeframe: Second and third trimesters of pregnancy

Interventionng/ML/day (Mean)
AUC -1AUC - 2
Part 1115136

[back to top]

Mean Birth Weight

Birth weight as measured in grams (NCT00439374)
Timeframe: Delivery

InterventionGrams (Mean)
17 Alpha-hydroxyprogesterone Caproate2855
Placebo2824

[back to top]

Number of Participants Who Reported Side Effects

Number of participants who reported any side effect, nausea, urticaria, and/or an issue at the injection site (NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

,
InterventionParticipants (Count of Participants)
AnyInjection siteUrticariaNausea
17 Alpha-hydroxyprogesterone Caproate223217107
Placebo220209210

[back to top]

Number of Participants Meeting the Composite Adverse Perinatal Outcome and Components

comprised of fetal or infant death, respiratory distress syndrome, intraventricular hemorrhage (grades 3 and 4), periventricular leukomalacia, necrotizing enterocolitis (stage II and III), Bronchopulmonary dysplasia /chronic lung disease, retinopathy of prematurity (stage III or higher), early onset sepsis (NCT00439374)
Timeframe: within 72 hours of delivery

,
InterventionParticipants (Count of Participants)
Composite Outcome TotalFetal DeathNeonatal DeathRespiratory Distress SyndromeBronchopulmonary dysplasiaNecrotizing enterocolitis, grade II or IIIIntraventricular Hemorrhage, Grade III or IVPeriventricular LeukomalaciaEarly-onset SepsisRetinopathy of prematurity, grade II or IV
17 Alpha-hydroxyprogesterone Caproate234613322431
Placebo3018165511113

[back to top]

Number of Participants Delivering Before 37 Weeks Gestation

Number of participants delivering before 37 weeks gestation by indication (NCT00439374)
Timeframe: Delivery before 37 weeks gestation

,
InterventionParticipants (Count of Participants)
Total Delivery <37 wkSpontaneousMedically indicatedFetal loss/abortion <20 wk
17 Alpha-hydroxyprogesterone Caproate8254271
Placebo8055250

[back to top]

Number of Neonates Who Measured Small for Gestational Age

Birth weight percentile and small for gestational age <10th percentile based on number of weeks and gender. (NCT00439374)
Timeframe: Delivery

,
InterventionParticipants (Count of Participants)
< 10th percentile< 3rd percentile
17 Alpha-hydroxyprogesterone Caproate5415
Placebo4714

[back to top]

Birth Weight by Count of Participants

Birth weight by count of participants < 2500 grams and < 1500 grams (NCT00439374)
Timeframe: Delivery

,
InterventionParticipants (Count of Participants)
Birth weight < 2500gBirth weight < 1500g
17 Alpha-hydroxyprogesterone Caproate7223
Placebo7529

[back to top]

Number of Participants With Preterm Premature Rupture of Membranes

(NCT00439374)
Timeframe: <37 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate25
Placebo24

[back to top]

Number of Participants With Gestational Diabetes Mellitus

(NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate15
Placebo13

[back to top]

Number of Participants With Apgar Score of Less Than 7 at 5 Minutes

The Apgar score is a simple method of quickly assessing the health and vital signs of a newborn baby created by and named after Dr. Virginia Apgar. Apgar testing assesses Appearance, Pulse, Grimace and Activity in a newborn and is typically done at one and five minutes after a baby is born, and it may be repeated at 10, 15, and 20 minutes if the score is low. The five criteria are each scored as 0, 1, or 2 (two being the best), and the total score is calculated by then adding the five values obtained. Agar scores of 0-3 are critically low, 4-6 are below normal, and indicate that the baby likely requires medical intervention, scores of 7+ are considered normal. The lower the Apgar score, the more alert the medical team should be to the possibility of the baby requiring intervention. Some components of the Apgar score are subjective, and there are cases in which a baby requires urgent medical treatment despite having a high Apgar score. (NCT00439374)
Timeframe: 5 minutes post delivery

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate15
Placebo19

[back to top]

Number of Participants Who Visited the Hospital Due to Preterm Labor

Number of participants who visited the hospital due to preterm labor before 37 weeks gestation (NCT00439374)
Timeframe: Between randomization and 37 weeks gestation

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate145
Placebo151

[back to top]

Number of Participants Who Underwent Tocolytic Therapy

Number of participants who underwent tocolytic therapy during pregnancy (NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate35
Placebo42

[back to top]

Number of Participants Who Underwent Corticosteroid Therapy

Number of participants who underwent corticosteroid therapy in pregnancy (NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate55
Placebo51

[back to top]

Number of Participants Who Had Cesarean Delivery

(NCT00439374)
Timeframe: delivery

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate67
Placebo63

[back to top]

Number of Participants Who Had a Cerclage Placement

Number of participants who had a cerclage placement (NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate6
Placebo4

[back to top]

Number of Participants Who Experienced Placental Abruption

(NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate11
Placebo15

[back to top]

Number of Participants Who Experienced Chorioamnionitis

(NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate29
Placebo20

[back to top]

Number of Participants Who Delivered Before 35 Weeks Gestation

Delivery before 35 weeks gestation (NCT00439374)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate44
Placebo53

[back to top]

Number of Participants Who Delivered Before 32 Weeks Gestation

Delivery before 32 weeks gestation (NCT00439374)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate28
Placebo32

[back to top]

Number of Neonates With a Major Congenital Anomaly

Presence of a major congenital anomaly at birth (NCT00439374)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate6
Placebo2

[back to top]

Number of Participants Who Delivered Before 28 Weeks Gestation

Delivery before 28 weeks gestation (NCT00439374)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate15
Placebo22

[back to top]

Number of Participants Experiencing Gestational Hypertension or Preeclampsia

(NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate46
Placebo40

[back to top]

Number of Participants Experiencing Cholestasis

(NCT00439374)
Timeframe: Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate1
Placebo0

[back to top]

Number of Neonates With Patent Ductus Arteriosus

Number of neonates diagnosed with the heart defect patent ductus arteriosus (NCT00439374)
Timeframe: Delivery through neonatal discharge

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate2
Placebo8

[back to top]

Number of Neonates Experiencing Seizures

Number of neonates experiencing seizures from delivery to hospital discharge (NCT00439374)
Timeframe: Delivery through neonatal discharge

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate1
Placebo2

[back to top]

Number of Neonates Admitted to NICU

Admission to the neonatal intensive care unit (NCT00439374)
Timeframe: Delivery through hospital discharge

InterventionParticipants (Count of Participants)
17 Alpha-hydroxyprogesterone Caproate63
Placebo69

[back to top]

Median Length of NICU Stay

Median length of stay in the neonatal intensive care unit in days (NCT00439374)
Timeframe: NICU admission through NICU discharge

Interventiondays (Median)
17 Alpha-hydroxyprogesterone Caproate17
Placebo15.5

[back to top]

Mean Gestational Age at Delivery

Mean gestational age at delivery (NCT00439374)
Timeframe: Delivery

Interventionweeks (Mean)
17 Alpha-hydroxyprogesterone Caproate37.6
Placebo37.4

[back to top]

Preterm Birth

Delivery below 34 weeks gestation (NCT00579553)
Timeframe: From 16-20 weeks gestation through preterm delivery

,
InterventionParticipants (Count of Participants)
Delivery less than 34 weeksDelivery less than 28 weeks
Intramuscular Progesterone137
Vaginal Progesterone148

[back to top]

Gestational Age at Delivery

Mean gestational age at delivery (NCT00579553)
Timeframe: From 16-20 weeks gestation through preterm delivery

InterventionWeeks gestation (Mean)
Intramuscular Progesterone35.8
Vaginal Progesterone36.3

[back to top]

Mean Neonatal Birth Weight

(NCT00579553)
Timeframe: At delivery

Interventiongrams (Mean)
Intramuscular Progesterone2680.6
Vaginal Progesterone2771.6

[back to top]

Preterm Birth

Delivery before 37 weeks gestation. (NCT00579553)
Timeframe: From 16-20 weeks gestation through preterm delivery

InterventionParticipants (Count of Participants)
Intramuscular Progesterone29
Vaginal Progesterone30

[back to top]

Preterm Birth Prior to 37 Weeks Gestation

(NCT01004029)
Timeframe: Up to 37 weeks

InterventionParticipants (Count of Participants)
Vehicle125
17P (Hydroxyprogesterone Caproate Injection)257

[back to top]

Preterm Birth Prior to 32 Weeks Gestation

(NCT01004029)
Timeframe: Up to 32 weeks

InterventionParticipants (Count of Participants)
Vehicle30
17P (Hydroxyprogesterone Caproate Injection)54

[back to top]

Preterm Birth <35 Weeks Gestation

Determine if treatment with 17P reduces the rate of preterm birth < 35 weeks, 0 days of gestation in women with a previous singleton spontaneous preterm delivery. (NCT01004029)
Timeframe: Up to 35 weeks

InterventionParticipants (Count of Participants)
Vehicle66
17P (Hydroxyprogesterone Caproate Injection)122

[back to top]

Neonatal Deaths With ≥24 Weeks Gestational Age

Neonatal death (from minutes after birth until 28 days of life) occurring in liveborns born at 24 weeks gestation or greater (NCT01004029)
Timeframe: Until 28 days of life or discharge from the NICU whichever occurred later.

InterventionParticipants (Count of Participants)
Vehicle2
17P (Hydroxyprogesterone Caproate Injection)3

[back to top]

Fetal/Early Infant Death

Defined as spontaneous abortion/miscarriage (delivery from 16 weeks 0 days through 19 weeks 6 days of gestation) or neonatal death occurring in liveborns born at less than 24 weeks gestation or stillbirth (antepartum or intrapartum death from 20 weeks gestation through term), in the 17P group compared to the vehicle group (NCT01004029)
Timeframe: Delivery from 16 weeks 0 days through 19 weeks 6 days of gestation; or neonatal death occurring in liveborns born at less than 24 weeks gestation; or stillbirth (antepartum or intrapartum death) from 20 weeks gestation through term).

InterventionParticipants (Count of Participants)
Vehicle11
17P (Hydroxyprogesterone Caproate Injection)19

[back to top]

Neonatal Composite Index (NCI)

The composite index is defined as a liveborn neonate with any of the following occurring at any time during the birth hospitalization up through discharge from the NICU: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis or proven sepsis. (NCT01004029)
Timeframe: Until 28 days of life or discharge from the neonatal intensive care unit (NICU), whichever occurred later.

InterventionParticipants (Count of Participants)
Vehicle28
17P (Hydroxyprogesterone Caproate Injection)61

[back to top]

Stillbirths

Defined as all stillbirths/fetal deaths/in utero fetal losses occurring from 20 weeks gestation until term. (NCT01004029)
Timeframe: 20 weeks gestation until term

InterventionParticipants (Count of Participants)
Vehicle3
Hydroxyprogesterone Caproate Injection, 250 mg/mL12

[back to top]

Number of Participants With Achievement of 34 Weeks Gestation

Delayed delivery until 34 weeks gestation. (NCT01050647)
Timeframe: From enrollment until delivery, an average of 34 weeks

InterventionParticipants (Count of Participants)
17-hydroxyprogesterone Caproate0
Castor Oil Injections0

[back to top]

Number of Participants With Neonatal Respiratory Distress Syndrome

(NCT01050647)
Timeframe: From delivery until neonatal hospital discharge, assessed up to 2 months

InterventionParticipants (Count of Participants)
17-hydroxyprogesterone Caproate7
Castor Oil Injections10

[back to top]

Number of Participants With Neonatal Necrotizing Enterocolitis

(NCT01050647)
Timeframe: From delivery to neonatal discharge, assessed up to 2 months

InterventionParticipants (Count of Participants)
17-hydroxyprogesterone Caproate2
Castor Oil Injections1

[back to top]

Number of Participants With Neonatal Grade III - IV Intraventricular Hemorrhage

(NCT01050647)
Timeframe: From delivery until neonatal hospital discharge, assessed up to 2 months

InterventionParticipants (Count of Participants)
17-hydroxyprogesterone Caproate1
Castor Oil Injections2

[back to top]

Neonatal Length of NICU and Total Hospital Stay Assessed as Number of Days

(NCT01050647)
Timeframe: From birth to discharge form delivery hospital, assessed up to 2 months

Interventiondays (Mean)
17-hydroxyprogesterone Caproate39
Castor Oil Injections50

[back to top]

Length of Latency Assessed as Number of Days

(NCT01050647)
Timeframe: From rupture of membranes until delivery, assessed up to 34 weeks of gestation

Interventiondays (Median)
17-hydroxyprogesterone Caproate14.5
Castor Oil Injections8

[back to top]

Gestational Age at Delivery

Gestational age is measured in weeks, from the first day of the woman's last menstrual cycle to the date the baby was born. (NCT01119963)
Timeframe: Measured from day of last menstrual cycle to day of birth and measured in weeks.

Interventionweeks. (Mean)
17-alpha Hydroxyprogesterone Caproate, Makena®29.2
Placebo29.5

[back to top]

Duration of Latency Period

"Secondary Outcomes:~- Duration of latency period (time from randomization to birth)" (NCT01119963)
Timeframe: average number of days measured from day of study entry until day of delivery

Interventiondays (Mean)
17-alpha Hydroxyprogesterone Caproate, Makena®17.1
Placebo17.0

[back to top]

Clinician Assessment of Ease of Drug Preparation

"Investigate the clinician's assessment of the ease of drug preparation associated with the administration of Makena® via subcutaneous auto-injector versus intramuscular injection as measured by a categorical scale.~Scores were as follows: completely dissatisfied = -3; mostly dissatisfied = -2, somewhat dissatisfied = -1, neither satisfied nor unsatisfied = 0, somewhat satisfied = 1, mostly satisfied = 2, completely satisfied = 3" (NCT02937766)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Treatment A2.8
Treatment B2.5

[back to top]

Clinician Assessment of Ease of Injection Technique

"Investigate the clinician's assessment of the ease of injection technique associated with the administration of Makena® via subcutaneous auto-injector versus intramuscular injection as measured by a categorical scale.~Scores were as follows: completely dissatisfied = -3; mostly dissatisfied = -2, somewhat dissatisfied = -1, neither satisfied nor unsatisfied = 0, somewhat satisfied = 1, mostly satisfied = 2, completely satisfied = 3" (NCT02937766)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Treatment A2.8
Treatment B2.3

[back to top]

Comparison of Average Pain Intensity

"Comparison of average pain intensity associated with the administration of Makena® via subcutaneous autoinjector versus intramuscular injection (averaged over 4 visits).~Score on a scale: 0 (No Pain) up to 10 (Worst Pain Imaginable)" (NCT02937766)
Timeframe: 4 weeks

InterventionParticipants with Injection Site Pain (Number)
Treatment A3
Treatment B2

[back to top]

Comparison of AUC (0-168)

Comparison of PK Parameter AUC (0-168) for the Primary PK Population (NCT02940522)
Timeframe: 9 weeks

Interventionhr x ng/mL (Geometric Mean)
Treatment A813
Treatment B790

[back to top]

Comparison of t1/2

Comparison of PK parameter t1/2 for the Primary PK Population (NCT02940522)
Timeframe: 9 weeks

Interventionhr (Geometric Mean)
Treatment A212
Treatment B185

[back to top]

Comparison of Elimination Rate Constant

Comparison of the elimination rate constant for the Primary PK Population (NCT02940522)
Timeframe: 9 weeks

Intervention1/hr (Geometric Mean)
Treatment A0.0033
Treatment B0.0038

[back to top]

Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf]

Comparison of areas under the curve (AUC) to the last time with a concentration ≥ LLOQ [AUC0-t] and to infinity [AUCinf] for the Primary PK Population (NCT02940522)
Timeframe: 9 weeks

,
Interventionhr x ng/mL (Geometric Mean)
AUC(0-t)AUC(inf)
Treatment A2,3132,469
Treatment B2,0982,175

[back to top]

Comparison of Tmax

Comparison of PK parameter Tmax for the Primary PK population (NCT02940522)
Timeframe: 9 weeks

Interventionhr (Geometric Mean)
Treatment A48.1
Treatment B49.7

[back to top]

Comparison of the Maximum Plasma Concentration (Cmax)

Comparison of the maximum plasma concentration (Cmax) for the Primary PK Population (NCT02940522)
Timeframe: 9 weeks

Interventionng/mL (Geometric Mean)
Treatment A7.88
Treatment B6.91

[back to top]

Survival A

days from first injection to spontaneous preterm delivery (NCT03292731)
Timeframe: time in days from first injection to spontaneous preterm delivery

Interventiondays (Mean)
Ancillary-250 mg150
RCT Group 250 mg Dose144
RCT Group -500 mg Dose145
Summarized OHPC145

[back to top]

Relationship Between 17-OHPC Concentration and Spontaneous Preterm Birth - A Concentration-Response Analysis

relationship between the rate of spontaneous preterm birth ( delivery < 37 weeks) and drug concentration obtained at 26-30 weeks among those with a blood sample and adherent to study protocol (n=116) (NCT03292731)
Timeframe: 26-30 week blood sample after a minimum of 7 injections among those with a blood sample and compliant with protocol(n=116)

InterventionParticipants (Count of Participants)
Ancillary -250 mg1
RCT Group 250 mg Dose9
RCT Group -500 mg Dose12
Summarized OHPC22

[back to top]

Preterm Birth by Dosing Group

rate of preterm birth according to dosing group. Subjects were the same cohort in spec aims 1 and 2 . They were compliant with protocol, had a 26-30 week blood sample and did not miss more than 2 injections. (NCT03292731)
Timeframe: from enrollment till preterm delivery

InterventionParticipants (Count of Participants)
250 mg Dose7
500 mg Dose9

[back to top]

NICU Admission

Infants admitted to the NICU (NCT03292731)
Timeframe: any admission to the NICU from time of delivery to time of discharge from the hospital up to 30 days or transfer to another facility

InterventionParticipants (Count of Participants)
250 mg Dose11
500 mg Dose16
All RCT Groups27

[back to top]

Composite Neonatal Outcome

Composite NN outcome (fetal death, neonatal death (NND), respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage 3 or 4, retinopathy of prematurity, hypoxic-ischemic encephalopathy, seizures.) and NICU admission (NCT03292731)
Timeframe: till discharge from nicu up to 30 days

InterventionParticipants (Count of Participants)
Ancillary- 250 mg Dose3
RCT - 250 mg Dose10
RCT - 500 mg Dose12
Summarized 17-OHPC25

[back to top]

Survival B

days from when the 26-30 week blood sample was obtained to the gestation at spontaneous preterm birth. All blood samples were obtained after at least 7 injections were give by which time steady state would have been achieved. This analysis was limited to those with a 26-30 week blood sample who were compliant with the protocol (NCT03292731)
Timeframe: days from blood sample time to spontaneous preterm delivery

Interventiondays (Mean)
Ancillary -250 mg74
RCT Group 250 mg Dose73
RCT Group -500mg Dose73
Summarized OHPC73

[back to top]

Comparison of Plasma Concentration of 17-OHPC According to Dose

"Plasma concentrations of 17-OHPC after 250 or 500 mg dose. Subjects were compliant with protocol up to the 26-30 week blood draw and had a blood sample available . This included subjects with indicated preterm birth and was not limited to those with spontaneous PTB. Plasma concentration among those receiving the 250 mg dose are compared to those receiving 500 mg dose.~Those receiving the 250 mg dose include both the RCT and ancillary groups." (NCT03292731)
Timeframe: Blood sample obtained at 26-30 weeks after a minimum of 7 injections and compliant with study protocol

Interventionng/ml (Median)
250 mg Dose8.6
500 mg Dose16.2

[back to top]

Number of Infants With 1-minute Apgar Score <7

"Apgar score of less than 7 at 1 minute of life. Apgar stands for Appearance, Pulse, Grimace, Activity, and Respiration and is a quick test rated on a scale of 1-10 performed on a baby at one minute of life to determine how well the baby tolerated the birth process. Scores 7 and above are generally normal, 4 to 6 fairly low, and 3 and below are generally regarded as critically low." (NCT03297216)
Timeframe: 1 minute of life

InterventionParticipants (Count of Participants)
250 mg 17P12
Placebo9

[back to top]

Number of Infants With Birth Weight <10th Percentile for Gestational Age

Infant born with a weight below the 10th percentile for gestational age (NCT03297216)
Timeframe: Birth

InterventionParticipants (Count of Participants)
250mg 17P95
Placebo93

[back to top]

Number of Neonatal Deaths

Death of an infant following live birth (NCT03297216)
Timeframe: Birth through 28 days postpartum

InterventionParticipants (Count of Participants)
250 mg 17P14
Placebo7

[back to top]

Number of Participants Experiencing Preterm Birth <28 Weeks

Delivery prior to 28 gestational weeks (NCT03297216)
Timeframe: At delivery, up to 28 weeks of gestation

InterventionParticipants (Count of Participants)
250 mg 17P3
Placebo5

[back to top]

Number of Participants Experiencing Preterm Birth <34 Weeks

Delivery prior to 34 gestational weeks (NCT03297216)
Timeframe: At delivery, up to 34 weeks of gestation

InterventionParticipants (Count of Participants)
250 mg 17P14
Placebo16

[back to top]

Number of Participants Experiencing Preterm Birth <37 Weeks

Delivery prior to 37 gestational weeks (NCT03297216)
Timeframe: At delivery, up to 37 weeks of gestation

InterventionParticipants (Count of Participants)
250 mg 17P31
Placebo35

[back to top]

Number of Infants With Birth Weight <3rd Percentile for Gestational Age

Infant born with a weight below the 3rd percentile for gestational age (NCT03297216)
Timeframe: Birth

InterventionParticipants (Count of Participants)
250 mg 17P28
Placebo47

[back to top]

Number of Participants Experiencing Preterm Births or Stillbirths

A composite of live births prior to 37 weeks of gestation or stillbirth occurring at any gestational age (NCT03297216)
Timeframe: At delivery, up to 37 weeks of gestation for live births and up to approximately 40 weeks of gestation for stillbirths

InterventionParticipants (Count of Participants)
250 mg 17P36
Placebo36

[back to top]

Number of Infants Who Experienced Maternal-to-Child HIV Transmission

Confirmed HIV infection in an infant (NCT03297216)
Timeframe: At 6 weeks of life

InterventionParticipants (Count of Participants)
250 mg 17P1
Placebo1

[back to top]

Number of Participants Experiencing Spontaneous Delivery <28 Weeks

Delivery prior to 28 weeks of gestation that was initiated spontaneously, without provider intervention (NCT03297216)
Timeframe: At delivery, up to 28 weeks of gestation

InterventionParticipants (Count of Participants)
250 mg 17P3
Placebo4

[back to top]

Number of Participants Experiencing Spontaneous Delivery <34 Weeks

Delivery prior to 34 weeks of gestation that was initiated spontaneously, without provider intervention (NCT03297216)
Timeframe: At delivery, up to 34 weeks of gestation

InterventionParticipants (Count of Participants)
250 mg 17P10
Placebo11

[back to top]

Number of Participants Experiencing Spontaneous Delivery <37 Weeks

Delivery prior to 37 weeks of gestation that was initiated spontaneously, without provider intervention (NCT03297216)
Timeframe: At delivery, up to 37 weeks of gestation

InterventionParticipants (Count of Participants)
250 mg 17P25
Placebo26

[back to top]

Number of Participants Experiencing Stillbirth

Participants who had a fetus born without signs of life at any gestational age (NCT03297216)
Timeframe: At delivery, up to approximately 40 weeks of gestation

InterventionParticipants (Count of Participants)
250 mg 17P10
Placebo11

[back to top]

Number of Infants With 5-minute Apgar Score <7

"Apgar score of less than 7 at 5 minutes of life. Apgar stands for Appearance, Pulse, Grimace, Activity, and Respiration and is a quick test rated on a scale of 1-10 performed on a baby at five minutes of life to assess how well the baby is doing following delivery. Scores 7 and above are generally normal, 4 to 6 fairly low, and 3 and below are generally regarded as critically low." (NCT03297216)
Timeframe: 5 minutes of life

InterventionParticipants (Count of Participants)
250 mg 17P7
Placebo2

[back to top]

Change in Mean Trough Levels of 17-OHPC in the Three Groups at 20-22 Weeks, 27-29 Weeks and 34-36 Weeks.

Blood levels (NCT03433040)
Timeframe: From enrollment to 36 weeks of pregnancy

,,
Interventionng/ml (Mean)
20-22 weeks27-29 weeks34-36 weeks
Non Obese10.111.515.2
Obese18.017.924.6
Obese - Control13.08.111.1

[back to top]

Gestational Age at Delivery

Gestational age at delivery in weeks . Too few to dichotomize to <37, 34 and 32 weeks as previously planned. (NCT03433040)
Timeframe: Up to 37 weeks

InterventionWeeks (Mean)
Non Obese36.7
Obese - Control38.4
Obese32.2

[back to top]